The combination of our proprietary Partial Wave Spectroscopy (PWS) NanocytologyTM platform and field carcinogenesis enables a paradigm shift; we don’t need to examine the tumor itself to stratify an individual’s cancer risk. We can examine cells at the nanoscale, where mutations and cellular changes can be detected long before they are evident at the microscopic level.
This means that while biopsied cells may appear to be normal to a pathologist using a standard microscope, PWS NanocytologyTM can detect profound changes in the nanoscale architecture of the same cells.
Our technology platform measures the disorder strength of the nanoscale organization of the cell, one of the earliest signs of carcinogenesis and likely a strong and clinically significant biomarker for the presence of cancer. (Scroll down to Field Effect to read why surrogate cells are clinically relevant.)